SHPTP2 is a ubiquitously expressed tyrosine-specific protein phosphatase that contains two aminoterminal Src homology 2 (SH2) domains responsible for its association with tyrosine-phosphorylated proteins. In this study, expression ofdominant interfering mutants of SHPTP2 was found to inhibit insulin stimulation of c-fos reporter gene expression and activation of the 42-kDa (Erk2) and 44-kDa (Erkl) mitogen-activated protein kinases. Cotransfection of dominant interfering SHPTP2 mutants with v-Ras or Grb2 indicated that SHPTP2 regulated insulin signaling either upstream of or in parallel to Ras function. Furthermore, phosphotyrosine blotting and immunoprecipitation identified the 125-kDa focal adhesion kinase (pp125FAK) as a substrate for insulin-dependent tyrosine dephosphorylation. These data demonstrate that SHPTP2 functions as a positive regulator of insulin action and that insulin signaling results in the dephosphorylation of tyrosine-phosphorylated ppl25FAK.
The insulin receptor is a ligand-stimulated transmembrane protein-tyrosine kinase that phosphorylates itself as well as intracellular substrates on specific tyrosine residues (1, 2). One proximal intracellular target for the kinase-activated insulin receptor has been identified as a 185-kDa protein, termed insulin receptor substrate 1 (IRS1) (3, 4) . This molecule contains several insulin receptor-specific tyrosine phosphorylation sites that provide recognition signals for the binding of specific Src homology 2 (SH2) domain-containing proteins (5, 6) . The interaction of IRS1 with signaling proteins containing multiple SH2 domains provides a mechanism by which insulin can modulate the function of several distinct pathways. For example, activation of phosphatidylinositol (PI) 3-kinase activity occurs upon the association of the p85 subunit of the PI 3-kinase with tyrosine-phosphorylated IRS1 (7) (8) (9) . It has been suggested that the insulin activation of Ras function results from the interaction and/or appropriate targeting of the guanine nucleotide exchange factor Sos with IRS1 (6, 10) . This is thought to occur via the constitutive association of the Src homology 3 (SH3) domains of the adapter protein Grb2 with the C-terminal domain of Sos (Grb2/Sos complex) and subsequent binding of the Grb2 SH2 domain to tyrosinephosphorylated IRS1 (10, 11) .
Recently, several groups have identified a ubiquitously expressed 68-kDa tyrosine-specific protein phosphatase, SHPTP2 (also termed Syp, PTP1D, SHPTP3, PTP2C, or PTPL1), that contains two N-terminal SH2 domains and a C-terminal catalytic domain (12) (13) (14) (15) (16) (17) . The SH2 domains of this phosphatase mediate the binding of SHPTP2 to tyrosinephosphorylated epidermal growth factor receptor, plateletderived growth factor receptor, and IRS1, resulting in the activation of protein-tyrosine-phosphatase activity (18) (19) (20) (21) . Although protein tyrosine phosphatase activity is generally thought to function as the inactivating arm of receptor kinase signaling pathways, in the case of T-cell receptor signaling, the CD45 protein-tyrosine-phosphatase is essential for downstream biological responsiveness (22, 23 4To whom reprint requests should be addressed.
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MAP Kinase Activity. MAP kinase activity from cell lysates was determined as described (25 
RESULTS
To assess the role of the SHPTP2 protein-tyrosinephosphatase in mediating insulin signaling, we examined the insulin activation of c-fos transcription by using a SRE-Luc reporter gene (Fig. 1) . The c-fos SRE is highly sensitive to transcriptional activation by insulin and serves as a convenient downstream assay for insulin signaling (24, 27, 28) . In CHO/IR cells, insulin-stimulated SRE-Luc activity was -10-fold in control cells and was not affected by expression of the wild-type SHPTP2 (PTP2). In contrast, expression of either a point mutant in which the essential catalytic cysteine residue was replaced with serine (C/SPTP2) or the SH2 domains of SHPTP2 (PTP2SH2) markedly inhibited the insulin stimulation of SRE-Luc reporter activity. This inhibition of insulin signaling was specific, in that expression of the c-Src SH2 domain (srcSH2) did not affect insulin stimulation of SRELuc activity. In addition, expression of the SHPTP2 mutants had no effect on the ability of PMA to increase SRE-Luc 15 A 10 10 w-0W expression (Fig. 1A) . The dominant interfering action of the SHPTP2 mutants was not a general property of all proteintyrosine-phosphatases (Fig. 1B) . Expression of another wildtype protein-tyrosine-phosphatase, PTP1B, or a PTP1B phosphatase-negative mutant (C/SPTP1B) had no significant effect on insulin stimulation of SRE-Luc reporter gene activity.
The Ras/MAP kinase pathway is one of the major routes responsible for growth factor activation of the c-fos SRE (reviewed in refs. [29] [30] [31] . Thus, to determine whether the inhibition of insulin-stimulated SRE-Luc activity by the dominant interfering SHPTP2 mutants occurred via a blockade of MAP kinase activation, we performed MAP kinase Western blots on extracts from control and insulin-treated cells ( Fig.  2A) . The predominant insulin-stimulated MAP kinase isoform in CHO/IR cells is the 42-kDa MAP kinase (Erk2), with relatively lower levels of the 44-kDa MAP kinase (Erkl). Subsequent to insulin treatment, both Erkl and Erk2 displayed the typical mobility shift due to tyrosine and threonine phosphorylation (32-34) in both control transfected cells ( Fig. 2A,  lanes 1 and 2) and cells transfected with wild-type SHPTP2 (lanes 3 and 4). In contrast, expression of either dominant interfering SHPTP2 mutant prevented the formation of the slower-mobility Erkl and Erk2 species in the presence of insulin ( Fig. 2A, lanes 5-8) .
To determine whether this inhibition of the insulinstimulated MAP kinase gel shift directly reflected changes in MAP kinase activity, we next examined MAP-2 phosphorylation from control and SHPTP2 transfected CHO/IR cells (Fig. 2B ). Control and wild-type SHPTP2-transfected cells displayed an -4-fold insulin stimulation of MAP kinase activity. In contrast, expression of the C/SPTP2 and PTP2SH2 mutants inhibited the insulin stimulation of MAP kinase activity, resulting in only 2.3-and 1.8-fold increases, respectively. The incomplete inhibition of insulin-stimulated MAP kinase activation was in agreement with the partial inhibition of insulin-stimulated SRE-Luc activity achieved under these transient transfection conditions (Fig. 1) . Together, these data demonstrate that at least one function of the SHPTP2 tyrosine-specific phosphatase is to transmit a positive insulin signal that results in the activation of MAP kinase activity.
Since MAP kinase has also been established as a down- (26) . Basal (open bars) and insulin (solid bars) stimulation of SRE-Luc reporter gene activity was then determined as described above. The amount of SRE-Luc activity determined in cell extracts was normalized for expression of RSV-,3Gal. Data are presented as means with SEM from four independent experiments each performed in triplicate.
Biochemistry: Yamauchi et ship between SHPTP2 function and that of Ras activation. As observed in Fig. 1 , insulin stimulated SRE-Luc activity 10-fold (Fig. 3A) . Similarly, expression of oncogenic viral Ras (v-Ras) also increased SRE-Luc activity compared with control cells. Furthermore, insulin treatment of cells transfected with v-Ras increased SRE-Luc reporter activity 22-fold compared with the 16-fold increase in v-Ras-transfected cells in the absence of insulin (P < 0.05). Although expression of the C/SPTP2 point mutant partially inhibited insulin stimulation of SRE-Luc activity (P < 0.05), this mutant had no effect on v-Ras stimulation of the reporter gene (Fig. 3A , compare bars 5 and 7). However, the dominant interfering C/SPTP2 point mutant did reduce the additional effect of insulin in cells which were both transfected with v-Ras and treated with insulin (compare bars 6 and 8; P < 0.05). These data suggest that SHPTP2 functions either upstream of or in a pathway parallel to Ras.
Recent studies have suggested that the adapter protein Grb2 can function as an upstream activator of Ras by complexing with and appropriately targeting the guanine nucleotide exchange factor Sos to Ras (38) (39) (40) (41) (42) . Consistent with these results, expression of Grb2 enhanced insulin stimulation of SRE-Luc activity "50% (P < 0.05; Fig. 3B ), most likely by an increased coupling efficiency of Sos to tyrosine-phosphory- lated IRS1 or Shc (10, 11, 43, 44) . Although expression of the C/SPTP2 mutant significantly reduced the insulin stimulation of SRE-Luc activity (P < 0.05), coexpression of the mutant phosphatase with Grb2 restored SRE-Luc activity to the level observed in control cells treated with insulin alone. The ability of Grb2 to partially circumvent the C/SPTP2 inhibition of downstream signaling in the presence of insulin further suggests that Grb2 may couple to the Ras/MAP kinase pathway via a pathway parallel to that used by SHPTP2.
To identify potential targets of SHPTP2 responsible for insulin downstream signaling, we analyzed phosphotyrosine Western blots of whole cell extracts from basal and insulinstimulated CHO/IR cells. Control transfected cells displayed an insulin stimulation of IRS1, insulin receptor 13 subunit, and pp6O (Fig. 4, lanes 1 and 2) . In addition, two bands in the vicinity of 50 kDa were also tyrosine phosphorylated and probably represent the 46-and 52-kDa forms of Shc (44) . Similarly, insulin stimulation of cells transfected with the wild-type SHPTP2 (Fig. 4, lanes 3 and 4) , the C/SPTP2 point mutant (lanes 5 and 6) , or the PTP2SH2 domain (lanes 7 there was a small but consistent increase in the extent of insulin-stimulated tyrosine phosphorylation of IRS1 from cells transfected with the dominant interfering SHPTP2 mutants (Fig. 4, compare lanes 6 and 8 with lanes 2 and 4) . Although the increase in IRS1 tyrosine phosphorylation was relatively small, these data are consistent with a recent report that SHPTP2 can dephosphorylate IRS1 in vitro (45) . In addition, expression of either the dominant interfering C/SPTP2 point mutant (Fig. 4, lanes 5 and 6) or the PTP2SH2 domain (lanes 7 and 8) resulted in increased tyrosine phosphorylation of diffuse bands at 120-130 kDa compared with the control cells (Fig. 4, lanes 1 and 2) or cells transfected with the wild-type SHPTP2 (lanes 3 and 4) .
In attempts to identify the components of these diffuse protein bands, we performed selective immunoprecipitation and phosphotyrosine Western blotting of several known tyrosine-phosphorylated proteins in this molecular size range. These data demonstrated that these bands were not the Ras GTPase-activating protein or the Src kinase ppl20 substrate (data not shown). In contrast, immunoprecipitation with an antibody directed against the 125-kDa FAK followed by phosphotyrosine Western blotting directly demonstrated that expression of the dominant interfering C/SPTP2 mutant resulted in a basal increase in ppl25FAK tyrosine phosphorylation (Fig. 5A, compare lanes 1 and 3) . The increased labeling in the C/SPTP2-transfected cells is consistent with a role for SHPTP2 in the tyrosine dephosphorylation of ppl25FAK. Surprisingly, however, insulin treatment induced tyrosine dephosphorylation of ppl25FAK in both control cells (Fig.  5A, lane 2) (Fig. SB) .
DISCUSSION
Protein phosphatase activity has generally been thought to function as the inactivating portion of signaling pathways by reversing the stimulatory phosphorylation event. However, phosphatase activity has been shown to play an important positive signaling role in the case of T-cell receptor signaling (22, 23) . In this regard, the data presented in this study suggest that the SHPTP2 protein-tyrosine-phosphatase plays an essential role in insulin signal propagation from the insulin receptor to MAP kinase and c-fos transcription. This was detected as an inhibition of insulin-stimulated MAP kinase gel shift and partial inhibition of MAP kinase activity and SRELuc expression in cells expressing inactive SHPTP2 mutants. This partial inhibition of downstream signaling reflects either an incomplete blockade of endogenous SHPTP2 function or the presence of alternative signaling pathways leading to MAP kinase activation. However, the extent of inhibition of MAP kinase activity was in proportion to the reduction in insulinstimulated SRE-Luc expression. This is consistent with the MAP kina3e functioning as an upstream kinase for the nuclear transcription factors SRF and p62TCF, which mediate SRE responsiveness (for review, see ref. 46 
